Compare AU
Compare DRUG vs. VDGR
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare ETF - Currency Hedged (DRUG) and the Vanguard Diversified Growth Index ETF (VDGR). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | VDGR | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 107 |
Median incremental investment | $967.00 | $1,052.75 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,875.72 | $3,240.54 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | VDGR | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | VDGR.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. The Fund seeks to achieve its objective by employing a passive investment strategy that tracks the weighted average return of the various indices of the Underlying Funds in which the Fund invests, in proportion to the SAA for the Fund, before takinginto account fees, expenses and tax |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | BHP Group Ltd. (3.01 %) Commonwealth Bank of Australia (2.40 %) CSL Ltd. (1.89 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Other (31.32 %) Financials (13.67 %) Information Technology (9.13 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | United States (39.83 %) Australia (38.22 %) Japan (3.61 %) |
Management fee | 0.57 % | 0.27 % |
Key Summary
DRUG | VDGR | |
|---|---|---|
Issuer | BetaShares | Vanguard |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | 28% S&P/ASX 300 Index - 20.5% MSCI World ex-Australia Index - 12.5% MSCI World ex Australia Hedged to AUD Index - 5% MSCI World ex-Australia Small Cap Index - 34% Other Benchmark |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.27 % |
Price | $8.12 | $63.54 |
Size | $191.120 million | $1.222 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.90 % | 5.01 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 22/11/2017 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | VDGR | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 107 |
Median incremental investment | $967.00 | $1,052.75 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,875.72 | $3,240.54 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | VDGR | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | VDGR |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |